AOD-9604
AOD9604 (Anti-Obesity Drug 9604) is a synthetic fragment of human growth hormone (HGH) that targets fat metabolism without raising IGF-1.
Total Price
฿1300
For research & laboratory use only. Not for human consumption.
Half-Life
30-60 minutes
Administration Route
Subcutaneous injection
Targeted Fat Breakdown
Activates lipolysis without stimulating IGF-1 or growth
No Glucose Impact
Does not affect blood sugar or insulin sensitivity
Growth Factor Activity
Retains bone-protective effects of HGH C-terminal fragment
Effect Timeline
Lipolytic signalling active; fat cell metabolism increases
Stubborn fat deposits begin mobilising
Visible reduction in body fat %, especially peripherally
Sustained fat loss without lean mass loss confirmed
Start — Week 2
Lipolytic signalling active; fat cell metabolism increases
Week 4
Stubborn fat deposits begin mobilising
Week 8
Visible reduction in body fat %, especially peripherally
Week 12
Sustained fat loss without lean mass loss confirmed
Mechanism of Action
Scientific Research
Obesity Reviews (2006)
Why Researchers Choose AOD9604
AOD9604 is studied wherever the goal is to isolate the fat-metabolising action of human growth hormone from its growth-promoting effects. Because the HGH fragment drives lipolysis without raising IGF-1, insulin or glucose, it is a clean tool for fat-metabolism research:
- Selective adipose-tissue lipolysis without IGF-1 or anabolic confounders
- Comparative lipolysis pharmacology against intact HGH and the related fragment 176-191
- Beta-3 adrenergic receptor activity studies in adipocytes
- Lipogenesis inhibition and fat-cell differentiation research
- Metabolic syndrome and abdominal-adiposity investigations
- Long-term safety profiling of lipolytic peptide fragments
Reconstitution and Storage
Reconstitution: use bacteriostatic water (1 to 2ml); swirl gently until the powder fully dissolves, do not shake. After reconstitution: keep refrigerated (2-8°C), use within 28 days, do not freeze, and protect from direct light.
Dosing at a Glance
Route
Subcutaneous injection
Frequency
Once daily
Typical research dose
250–500 mcg
Opens the calculator with this peptide preselected. Research reference only.